Survival Predictions for NSCLC Accurate With the Lung Cancer Prognostic Index
LCPI may be useful for guiding clinical trial eligibility.
The Lung Cancer Prognostic Index (LCPI) provides additional relevant prognostic data for patients with non-small cell lung cancer (NSCLC) and may lead to better outcomes, according to a study published in the British Journal of Cancer.
There are numerous prognostic models for patients with NSCLC, but their ability to provide accurate prognoses is limited as they are primarily dictated by staging. Staging plays an important role in determining therapy and predicting outcomes, but the heterogeneity even within stage groups of NSCLC suggests there are variable factors that affect prognosis in this patient population.
The study enrolled 695 patients with newly diagnosed NSCLC to derive the LCPI, and tested the index in 2 independent validation cohorts involving 763 patients.
The variables that had significant associations with overall survival (OS) assessed in the LCPI included stage, mutation status, histology, performance status, smoking history, respiratory comorbidity, weight loss, sex, and age.
According to the LCPI, the 2-year OS rates in the derivation cohort and two validation cohorts were respectively 84%, 77%, and 68% (LCPI 1 score ≤ 9); 61%, 61%, and 42% (LCPI2 score 10-13); 33%, 32%, and 14% (LCPI 3 score 14-16); 7%, 16%, and 5% (LCPI 4 score > 15).
The study shows that LCPI is a simple and generalizable scoring system, which may have utility in guiding trial eligibility or design, counseling patients, or standardizing mortality risk for epidemiological risk.
1. Marliese A, Wolfe R, Ball D, et al. Lung cancer prognostic index: a risk score to predict overall survival after the diagnosis of non-small-cell lung cancer [published online July 20, 2017]. Br J Cancer. doi: 10.1038/bjc.2017.232